Results 71 to 80 of about 8,373 (188)

Acute Iatrogenic Agranulocytosis: A Rare and Dire Case of an Adverse Drug Reaction to Be Aware

Case Reports in Hematology, 2020
Background. Iatrogenic agranulocytosis (IA), by nonchemotherapeutic drugs, is a rare adverse event, resulting in a neutrophil count under 0.5 × 109 cells/L with fever or other suggestive signs of infection. Methods.
Diogo André, Mónica Caldeira, Fabiana Gouveia, Rafael Nascimento, António Chaves, Maria Brazão   +5 more
doaj   +1 more source

Ticlopidine induced anemia and agranulocytosis

, 2000
A 63-year-old man with a history of transient ischemic attack had been treated with ticlopidine for 2 months. He presented with a 6-day history of fever, sore throat, and generalized weakness.
Sermez, Yurdaer, Keskin, Ali
core  

Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin

, 1994
Normal human platelets aggregated by thrombin undergo the release reaction and are not readily deaggregated by the combination of inhibitors hirudin, prostaglandin E1 (PGE1) and chymotrypsin.
C. Cimminiello, M. Cattaneo, R. L. Kinlough Rathbone, M. A. Packham, B. Akkawat, P. M. Mannucci   +5 more
core   +2 more sources

Effect of ticlopidine in the prevention of radiation enteropathy

, 2006
Impairment of vascular function is considered to play an important role in chronic radiation enteropathy. In this experimental study, the role of ticlopidine, an inhibitor of ADP-induced platelet aggregation, was investigated in radiation enteropathy. 80
Yildiz, F., Cengiz, M., Atahan, L., Haberal, I., Sokmensuer, C., Akyurek, S., Onal, C.   +6 more
core   +1 more source

Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.

PLoS ONE, 2015
There is a lack of consensus regarding which type of antiplatelet agent should be used in patients with peripheral arterial disease (PAD) and little is known on the advantages and disadvantages of dual antiplatelet therapy.
Konstantinos Katsanos, Stavros Spiliopoulos, Prakash Saha, Athanasios Diamantopoulos, Narayan Karunanithy, Miltiadis Krokidis, Bijan Modarai, Dimitris Karnabatidis   +7 more
doaj   +1 more source

Ticlopidine and clopidogrel

, 2001
Ticlopidine and clopidogrel in secondary stroke ...
Bogousslavsky J, Paciaroni M
core  

Ictère cholestatique sur ticlopidine : un nouveau cas

, 1994
[Cholestatic jaundice due to ticlopidine: a new case]
Weber, E, Donckier, Julian
core   +1 more source

A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine

Medical Devices: Evidence and Research, 2011
Ichiro Ikushima1, Kazuchika Yonenaga1, Hironao Iwakiri2, Hideki Nagoshi2, Haruhito Kumagai2, Yasuyuki Yamashita31Department of Radiology, 2Department of Cardiology, Miyakonojo Medical Association Hospital, Miyakonojo, Japan; 3Department of Diagnostic ...
Ikushima I, Yonenaga K, Iwakiri H, Nagoshi H, Kumagai H, Yamashita Y   +5 more
doaj  

A terapêutica médica da angina de peito.

Acta Médica Portuguesa, 1997
The angina pectoris crisis should be treated with nitroglycerin S.L.. In our days as in the 19th century, the non pharmacological therapeutic approach for angina pectoris (per se and to improve the free interval between crises) is still the same.
J G Clara
doaj   +1 more source

Clopidogrel-Induced Neutropenia after Coronary Stenting: Is Cilostazol a Good Alternative?

International Journal of Vascular Medicine, 2011
Dual antiplatelet therapy with aspirin plus thienopyridines has become the standard treatment of patients undergoing coronary stenting. Clopidogrel has mostly replaced the use of ticlopidine due to its more favourable adverse event profile. However, also
Massimo Montalto, Italo Porto, Antonella Gallo, Claudia Camaioni, Roberta Della Bona, Antonio Grieco, Filippo Crea, Raffaele Landolfi   +7 more
doaj   +1 more source